Abstract: CRD42021223812.
Introduction
The enzyme aldehyde dehydrogenase 2 (ALDH2) serves as the primary defense against acetaldehyde, a toxic byproduct of alcohol metabolism and environmental exposure. The rs671 genetic polymorphism (the *2 allele) significantly inhibits this enzyme's activity, creating a "double-edged sword" effect. While it reduces alcohol-related disease risk by making consumption unpleasant (the "Asian flush"), it simultaneously leads to the accumulation of toxic aldehydes, potentially increasing risks for cancer, cardiovascular disease, and neurodegeneration.
Despite hundreds of meta-analyses exploring these links, results remain contradictory or redundant, often due to "double-counting" primary studies. This paper presents a protocol for a quantitative umbrella review designed to map the complex relationship between ALDH2 rs671 and various human diseases, providing a definitive evidence map for this significant genetic variant in East Asian populations.
Methodology
This umbrella review sits at the top of the evidence hierarchy, synthesizing data from existing meta-analyses while correcting for overlapping primary studies. The systematic process ensures that the "explosive" but often conflicting body of evidence surrounding the ALDH2 rs671 variant is distilled into high-level insights.
Key methodological highlights include:
- Systematic Search: A multi-database search (PubMed, Embase, Cochrane, etc.) for meta-analyses published through July 2022.
- Quality Appraisal: Using a modified AMSTAR2 tool specifically tailored for observational genetic studies to grade the methodological quality of included reviews.
- Managing Overlap: The team will calculate the Corrected Covered Area (CCA) using a citation matrix to quantify shared primary data between meta-analyses, preventing inflated statistical confidence.
- Quantitative Synthesis: Recalculating Odds Ratios (OR) and Confidence Intervals (CI) from raw participant counts if data conflicts exist.
- Small-Study Effects: Utilizing Doi plots and the LFK index to detect publication bias more accurately than traditional funnel plots.
Inclusion Criteria and Datasets
The "dataset" for this umbrella review consists of previously published meta-analyses of genetic association studies. The protocol defines strict parameters to ensure the quality and relevance of the synthesized data.
The review focuses on meta-analyses examining the association between ALDH2 rs671 and outcomes such as cardiovascular disease, diabetes, cancer, neurodegenerative disease, and alcohol-induced medical disease. The underlying primary data must originate from cohort, nested case-control, or case-control studies. While global in scope, the focus is naturally on East Asian populations, where the rs671 variant affects approximately 40% of the population (roughly 560 million people).
Key Insights and Expected Results
A major innovation of this protocol is the explicit address of the "Overlap Problem." By recalculating effect sizes using a uniform genetic model (allelic, dominant, recessive, etc.), the authors aim to eliminate discrepancies caused by varying statistical assumptions across different research teams.
The final review will utilize a "stop-light" plot to categorize disease risks into Red (increased risk), Green (decreased risk), and Yellow (no significant effect). The expected evidence map will cover:
- Cardiovascular: Hypertension, CAD, myocardial infarction, and stroke.
- Metabolic: Diabetes mellitus and retinopathy.
- Oncology: Seven types of cancer, including esophageal, gastric, and liver.
- Neurology: Alzheimer’s and Parkinson’s diseases.
- Alcohol-related: Cirrhosis and pancreatitis.
Limitations and Future Work
The authors acknowledge constraints such as potential language bias (English-only search) and the inability to fully account for subtle genetic background differences without individual-level raw data. Furthermore, there may be a slight "recency gap" as the review will not include primary studies published after the most recent meta-analyses.
Once completed, this review will serve as a foundation for targeted prevention plans and precision medicine for the half-billion people carrying the ALDH2*2 allele.
Summary updated